PAVmed Inc. held an annual meeting of stockholders on June 18, 2025. During the meeting, stockholders elected Lishan Aklog, M.D. and Michael J. Glennon as Class C directors. Additionally, a proposal to approve the issuance of shares of the company's common stock upon exercise of pre-funded warrants sold in a private offering in February 2025 was also approved.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.